Assembly Biosciences (ASMB) Stock Price, Quote & News

Company Profile

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company als...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 509 4583

Website: www.assemblybio.com

Address:

Two Tower Place, 7th Floor, South San Francisco, United States

IN0V8 Sep. 1 at 4:21 PM

$ASMB Buy Mizuho raises target price to $53 from $45 UBS initiates coverage with buy rating and PT $52

0 · Reply

NYPD Sep. 1 at 2:31 PM

$ASMB ASMB: Assembly Biosciences price target raised to $53 from $45 at Mizuho Mizuho analyst Salim Syed raised the firm's price target on Assembly Biosciences to $53 from $45 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q2 reports. This update is part of the The Fly's breaking news coverage. To contact The Fly about this story, email [email protected]. For sales and API inquires, contact [email protected].

0 · Reply

NYPD Sep. 1 at 2:30 PM

$ASMB UBS initiated coverage of Assembly Biosciences with a Buy rating and $52 price target. The company has a "de-risked" antiviral platform, anchored by Gilead's development of the herpes simplex virus franchise, and upside from its wholly owned liver disease portfolio, the analyst tells investors in a research note. UBS believes GS-1179 can address the high unmet need in recurrent genital herpes, saying the Phase 2 outcome is de-risked by the Phase 1b data demonstrating a superior profile.

0 · Reply

NYPD Sep. 1 at 8:24 AM

$ASMB Assembly Bio Rated New Buy at UBS; PT $52 By Bloomberg Automation (Bloomberg) -- UBS initiated coverage of Assembly Biosciences Inc. with a recommendation of buy. PT set to $52, implies a 55% increase from last price.

0 · Reply

SearchFor911 Aug. 25 at 2:49 PM

$ASMB @NotHopeJustFacts missing you here mate. some more profits to come.

1 · Reply

DLTT4489 Aug. 24 at 8:34 PM

$ASMB something is brewing?? Will see

2 · Reply

Mirinda7878 Aug. 24 at 6:19 PM

$ASMB

1 · Reply

Thor1980 Aug. 24 at 3:43 PM

$TOP Come join us, and we’ll break the 52-week high. $LRN $ASMB $ATSC $PLTR

0 · Reply

SearchFor911 Aug. 21 at 2:33 PM

$ASMB hope everyone saw it: https://clinicaltrials.gov/study/NCT07762027 P2 for 6250 starting in October already.

1 · Reply

psychohaiko Aug. 20 at 9:30 AM

$ASMB Grüße gehen raus an Andy B. ! Desch koschtet! Muscht die Basics mache Junge! Wobei wahrscheinlich billiger als eine NBC-Mitgliedschaft am Ende. @Hailight überall am Profit-Maximieren;

0 · Reply

Assembly Biosciences price target raised to $53 from $45 at Mizuho

2026-09-01T09:25:18.000Z - 7 hours ago

Assembly Biosciences initiated with a Buy at UBS

2026-08-16T14:13:33.000Z - 16 days ago

Assembly Biosciences reports Q2 EPS (20c), consensus (52c)

Aug 13, 2026, 4:00 PM EDT - 18 days ago

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

Aug 13, 2026, 7:00 AM EDT - 19 days ago

Assembly Biosciences Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 19 days ago

Assembly Biosciences Earnings release: Q2 2026

Aug 1, 2026, 8:00 AM EDT - 4 weeks ago

Assembly Biosciences Slides: Corporate presentation

2026-06-15T11:07:41.000Z - 2 months ago

Assembly Biosciences price target raised to $45 from $40 at Mizuho

Jun 8, 2026, 8:40 AM EDT - 3 months ago

Assembly Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 11:00 AM EDT - 3 months ago

Assembly Biosciences Transcript: AGM 2026

Jun 3, 2026, 4:20 PM EDT - 3 months ago

Assembly Biosciences Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 4:05 PM EDT - 3 months ago

Assembly Biosciences Announces Upcoming Investor Conference Presentations

May 26, 2026, 4:05 PM EDT - 3 months ago

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

2026-05-22T11:28:01.000Z - 3 months ago

Assembly Biosciences announces expansion of ABI-6250 clinical development

May 22, 2026, 7:05 AM EDT - 3 months ago

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

May 22, 2026, 7:00 AM EDT - 3 months ago

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases

May 13, 2026, 7:35 PM EDT - 3 months ago

Assembly Biosciences Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:00 AM EDT - 3 months ago

Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026

May 11, 2026, 8:00 AM EDT - 4 months ago

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

2026-05-07T21:49:38.000Z - 4 months ago

Assembly Biosciences reports Q1 EPS (54c), consensus (64c)

May 7, 2026, 4:00 PM EDT - 4 months ago

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

May 7, 2026, 7:00 AM EDT - 4 months ago

Assembly Biosciences Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Assembly Biosciences Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Assembly Biosciences Slides: Corporate presentation

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Assembly Biosciences Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Assembly Biosciences Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 5 months ago

Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026

2026-04-06T10:45:10.000Z - 5 months ago

Assembly Biosciences price target raised to $43 from $39 at Guggenheim

GILD

2026-03-19T21:10:59.000Z - 5 months ago

Assembly Biosciences files $400M mixed securities shelf

Mar 19, 2026, 4:05 PM EDT - 5 months ago

Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights

Mar 19, 2026, 4:00 PM EDT - 5 months ago

Assembly Biosciences Annual report: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 5 months ago

Assembly Biosciences Earnings release: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 5 months ago

Assembly Biosciences Registration statement: Registration filing

Dec 22, 2025, 8:00 AM EST - 9 months ago

Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

GILD

Dec 8, 2025, 6:00 PM EST - 9 months ago

Assembly Biosciences Transcript: Study Result

Dec 8, 2025, 6:00 PM EST - 9 months ago

Assembly Biosciences Press release: Study Result

Dec 8, 2025, 6:00 PM EST - 9 months ago

Assembly Biosciences Slides: Study Result

2025-12-08T21:16:39.000Z - 9 months ago

Assembly Biosciences announces interim results from ABI-1179, ABI-5366 trials

GILD

Dec 8, 2025, 4:05 PM EST - 9 months ago

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

2025-11-20T12:10:09.000Z - 10 months ago

Assembly Biosciences price target raised to $40 from $29 at Mizuho

Nov 12, 2025, 11:00 AM EST - 10 months ago

Assembly Biosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-10T21:36:33.000Z - 10 months ago

Assembly Biosciences reports Q3 EPS (72c), consensus (65c)

Nov 10, 2025, 4:05 PM EST - 10 months ago

Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

Nov 10, 2025, 7:00 AM EST - 10 months ago

Assembly Biosciences Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Assembly Biosciences Quarterly report: Q3 2025

Nov 9, 2025, 6:00 PM EST - 10 months ago

Assembly Biosciences Slides: Corporate Presentation

2025-11-07T13:11:15.000Z - 10 months ago

Assembly Biosciences announces Phase 1b data for ABI-4334

Nov 7, 2025, 8:00 AM EST - 10 months ago

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

2025-10-14T20:25:22.000Z - 11 months ago

Assembly Biosciences files to sell 6.98M shares of commons stock for holders

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Assembly Biosciences Registration statement: Registration Filing

Oct 14, 2025, 7:00 AM EDT - 11 months ago

Assembly Biosciences Announces Upcoming Investor Conference Participation

2025-10-10T12:10:50.000Z - 11 months ago

Assembly Biosciences presents interim Phase 1b data for ABI-5366

Oct 10, 2025, 8:00 AM EDT - 11 months ago

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

2025-09-24T08:30:11.000Z - 1 year ago

Assembly Biosciences initiated with an Outperform at Citizens JMP

2025-09-08T11:45:12.000Z - 1 year ago

Assembly Biosciences price target raised to $39 from $31 at Guggenheim

Aug 8, 2025, 8:05 AM EDT - 1 year ago

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Assembly Biosciences Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Assembly Biosciences Earnings release: Q2 2025

Jul 26, 2025, 3:00 AM EDT - 1 year ago

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

Jun 25, 2025, 8:00 AM EDT - 1 year ago

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

Jun 4, 2025, 8:45 AM EDT - 1 year ago

Assembly Biosciences Transcript: Jefferies Global Healthcare Conference 2025

May 27, 2025, 4:05 PM EDT - 1 year ago

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

May 8, 2025, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

May 8, 2025, 4:00 PM EDT - 1 year ago

Assembly Biosciences Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Assembly Biosciences Quarterly report: Q1 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Assembly Biosciences Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Assembly Biosciences Proxy statement: Proxy Filing

Apr 9, 2025, 2:00 AM EDT - 1 year ago

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Assembly Biosciences Earnings release: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Assembly Biosciences Annual report: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Assembly Biosciences Registration statement: Registration Filing

Feb 26, 2025, 8:00 AM EST - 1 year ago

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Feb 20, 2025, 8:00 AM EST - 1 year ago

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Dec 26, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Nov 6, 2024, 6:00 PM EST - 1 year ago

Assembly Biosciences Earnings release: Q3 2024

Nov 6, 2024, 6:00 PM EST - 1 year ago

Assembly Biosciences Quarterly report: Q3 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Assembly Biosciences Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Assembly Biosciences Earnings release: Q2 2024

Jul 15, 2024, 8:00 AM EDT - 2 years ago

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Jun 10, 2024, 8:00 AM EDT - 2 years ago

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

May 22, 2024, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

May 8, 2024, 4:05 PM EDT - 2 years ago

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

May 8, 2024, 4:00 PM EDT - 2 years ago

Assembly Biosciences Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

Assembly Biosciences Earnings release: Q1 2024

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Assembly Biosciences Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Assembly Biosciences Proxy statement: Proxy Filing

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Assembly Biosciences Annual report: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Assembly Biosciences Earnings release: Q4 2023

Feb 8, 2024, 8:00 AM EST - 2 years ago

Assembly Biosciences Announces Effective Date of Reverse Stock Split

Jan 4, 2024, 8:00 AM EST - 2 years ago

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Dec 21, 2023, 7:00 AM EST - 2 years ago

Assembly Biosciences Proxy statement: Proxy Filing

Dec 21, 2023, 7:00 AM EST - 2 years ago

Assembly Biosciences Proxy statement: Proxy Filing

Dec 11, 2023, 7:00 AM EST - 2 years ago

Assembly Biosciences Proxy statement: Proxy Filing

Nov 10, 2023, 4:05 PM EST - 3 years ago

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 8, 2023, 8:00 AM EST - 3 years ago

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Nov 8, 2023, 8:00 AM EST - 3 years ago

Assembly Biosciences Quarterly report: Q3 2023

Nov 8, 2023, 8:00 AM EST - 3 years ago

Assembly Biosciences Earnings release: Q3 2023

Oct 17, 2023, 8:30 AM EDT - 3 years ago

Assembly Biosciences Transcript: Investor Update

Oct 17, 2023, 8:30 AM EDT - 3 years ago

Assembly Biosciences Slides: Investor Update

Oct 17, 2023, 7:00 AM EDT - 3 years ago

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

GILD

Oct 11, 2023, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

Oct 2, 2023, 8:00 AM EDT - 3 years ago

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

Sep 19, 2023, 4:05 PM EDT - 3 years ago

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

Aug 9, 2023, 8:00 AM EDT - 3 years ago

Assembly Biosciences Quarterly report: Q2 2023

Aug 9, 2023, 8:00 AM EDT - 3 years ago

Assembly Biosciences Earnings release: Q2 2023

Jul 17, 2023, 8:00 AM EDT - 3 years ago

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

Jun 7, 2023, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023

May 23, 2023, 4:05 PM EDT - 3 years ago

Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference

May 4, 2023, 4:05 PM EDT - 3 years ago

Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

May 4, 2023, 7:00 AM EDT - 3 years ago

Assembly Biosciences Quarterly report: Q1 2023

May 4, 2023, 7:00 AM EDT - 3 years ago

Assembly Biosciences Earnings release: Q1 2023

Apr 12, 2023, 8:00 AM EDT - 3 years ago

Assembly Biosciences Proxy statement: Proxy Filing

Apr 12, 2023, 8:00 AM EDT - 3 years ago

Assembly Biosciences Proxy statement: Proxy Filing

Mar 31, 2023, 8:00 AM EDT - 3 years ago

Assembly Biosciences Proxy statement: Proxy Filing

Mar 22, 2023, 4:05 PM EDT - 3 years ago

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Assembly Biosciences Annual report: Q4 2022

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Assembly Biosciences Earnings release: Q4 2022

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Assembly Biosciences Registration statement: Registration Filing

Jan 17, 2023, 7:00 AM EST - 3 years ago

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

IN0V8 Sep. 1 at 4:21 PM

$ASMB Buy Mizuho raises target price to $53 from $45 UBS initiates coverage with buy rating and PT $52

0 · Reply

NYPD Sep. 1 at 2:31 PM

0 · Reply

NYPD Sep. 1 at 2:30 PM

0 · Reply

NYPD Sep. 1 at 8:24 AM

0 · Reply

SearchFor911 Aug. 25 at 2:49 PM

$ASMB @NotHopeJustFacts missing you here mate. some more profits to come.

1 · Reply

DLTT4489 Aug. 24 at 8:34 PM

$ASMB something is brewing?? Will see

2 · Reply

Mirinda7878 Aug. 24 at 6:19 PM

$ASMB

1 · Reply

Thor1980 Aug. 24 at 3:43 PM

$TOP Come join us, and we’ll break the 52-week high. $LRN $ASMB $ATSC $PLTR

0 · Reply

SearchFor911 Aug. 21 at 2:33 PM

$ASMB hope everyone saw it: https://clinicaltrials.gov/study/NCT07762027 P2 for 6250 starting in October already.

1 · Reply

psychohaiko Aug. 20 at 9:30 AM

$ASMB Grüße gehen raus an Andy B. ! Desch koschtet! Muscht die Basics mache Junge! Wobei wahrscheinlich billiger als eine NBC-Mitgliedschaft am Ende. @Hailight überall am Profit-Maximieren;

0 · Reply

SearchFor911 Aug. 19 at 7:33 PM

$ASMB strong and steady. marching for that buyout.

0 · Reply

psychohaiko Aug. 19 at 2:43 PM

$ASMB Der Wolf im Stinkepelz, @Hailight beim entwickeln der deutschen Börsenkultur unersättlich; Sharedeals.de Aushängeschild <3

0 · Reply

ShinnosukeNohara Aug. 18 at 8:08 PM

$ASMB oops.. I was wrong😎✌️

0 · Reply

ShinnosukeNohara Aug. 18 at 12:57 PM

$ASMB get ready for another big drop. I smell it😎

0 · Reply

NYPD Aug. 18 at 12:05 PM

$ASMB HC Wainwright & Co. réitère son achat sur Assembly Biosciences, maintient un objectif de cours de 50 $ Benzinga Newsdesk (Benzinga France) L'analyste de HC Wainwright & Co., Patrick R. Trucchio, réitère sa recommandation Buy sur Assembly Biosciences (NASDAQ:ASMB) et maintient son objectif de cours à 50 dollars.© 2024 Benzinga | All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info).

0 · Reply